Is Sentinel Lymph Node Mapping Indicated for Isolated Local and In-Transit Recurrent Melanoma?

Yao, Katharine; Hsueh, Eddy C.; Essner, Richard; Foshag, Leland J.; Wanek, Leslie A.; Morton, Donald L.

doi:10.1097/01.sla.0000094440.50547.1d

Cited by 60 publications

(49 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although in-transit disease has a high probability of clinically occult regional nodal involvement and a positive sentinel node in the presence of in-transit metastasis portends a more ominous prognosis, the impact of SLNB on outcome remains unknown. 97 For patients for whom resection is not feasible, previous resections have been unsuccessful, or who refuse surgery, nonsurgical local approaches for treating stage III in-transit melanoma include intralesional injections, local ablation therapy, topical imiquimod, and RT. Intralesional Injections: A variety of agents have been tested as intralesional injections for melanoma.…”

Section: Local Therapymentioning

confidence: 99%

Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology

Coit¹,

Thompson²,

Algazi³

et al. 2016

J Natl Compr Canc Netw

219

167

View full text Add to dashboard Cite

OverviewIn 2016, an estimated 76,380 patients will be diagnosed with and approximately 10,130 patients will die of melanoma in the United States.1 However, these figures for new cases may represent a substantial underestimate, as many superficial and in situ melanomas treated in the outpatient setting are not reported. The incidence of melanoma continues to increase dramatically, at an overall rate of 33% for men and 23% women from 2002 to 2006.2 Melanoma is increasing in men more rapidly than any other malignancy, and in women more rapidly than any other malignancy except lung cancer. AbstractThis selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Melanoma focuses on adjuvant therapy and treatment of in-transit disease, because substantial changes were made to the recommendations for the 2016 update. Depending on the stage of the disease, options for adjuvant therapy now include biochemotherapy and highdose ipilimumab. Treatment options for in-transit disease now include intralesional injection with talimogene laherparepvec (T-VEC), a new immunotherapy. These additions prompted reassessment of the data supporting older recommended treatment options for adjuvant therapy and in-transit disease, resulting in extensive revisions to the supporting discussion sections. J Natl Compr Canc Netw 2016;14(4):450-473 NCCN Categories of Evidence and ConsensusCategory 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate. Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.All recommendations are category 2A unless otherwise noted.Clinical trials: NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. Please NoteThe NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ® ) are a statement of consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines ® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network ® (NCCN ® ) makes no representation or warranties of any kind regarding their content, use, or application and disclaims any responsibility for their applications or use in any way. The full NCCN Guidelines for Melanoma are not printed in this issue of JNCCN but can be accessed online at NCCN.org.© National Comprehensive Cancer Network, Inc. 2016, All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. Disclosures for the NCCN Melanoma ...

show abstract

Section: Local Therapymentioning

confidence: 99%

Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology

Coit¹,

Thompson²,

Algazi³

et al. 2016

J Natl Compr Canc Netw

219

167

View full text Add to dashboard Cite

show abstract

“…Repeat SNB has been used successfully in patients with a local relapse of melanoma and breast cancer [12][13][14]. This study shows that repeat SNB is feasible in locally recurrent penile carcinoma.…”

Section: Discussionmentioning

confidence: 88%

Repeat dynamic sentinel node biopsy in locally recurrent penile carcinoma

et al. 2010

View full text Add to dashboard Cite

show abstract

“…In these latter, there is a widespread evidence that the use of dye and radioactive tracer can improve accuracy and lower false-negative rates [1][2][3][4][5][6].…”

Section: Discussionmentioning

confidence: 99%

“…Clinicians seeking to determine prognoses for lymph node metastases first concentrated on developing methods of improving their gross identification of cancer in resected specimens, thereby improving likelihood of finding more metastatic deposits in lymph nodes. The sentinel node concept appears to fit to this search, having been validated as a prognostic tool and one of the most important methods for the multidisciplinary management of breast cancer and melanoma [1][2][3][4][5][6]. In contrast to breast carcinoma and malignant melanoma, where the technique is used as a determinant of the need for regional lymphadenectomy, in colorectal cancer lymphadenectomy remains a vital component of the oncological operation.…”

Section: Introductionmentioning

confidence: 99%